210 related articles for article (PubMed ID: 36839941)
1. HS 3D-SeboSkin Model Enables the Preclinical Exploration of Therapeutic Candidates for Hidradenitis Suppurativa/Acne Inversa.
Zouboulis CC; Hou X; von Waldthausen H; Zouboulis KC; Hossini AM
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839941
[TBL] [Abstract][Full Text] [Related]
2. 3D-SeboSkin Model for Human ex vivo Studies of Hidradenitis Suppurativa/Acne Inversa.
Hou X; Hossini AM; Nikolakis G; Balthasar O; Kurtz A; Zouboulis CC
Dermatology; 2022; 238(2):236-243. PubMed ID: 34077928
[TBL] [Abstract][Full Text] [Related]
3. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
4. Preservation of epidermal melanocyte integrity in an ex vivo co-culture skin model with sebocytes.
Abdel-Naser MB; Nikolakis G; Zouboulis CC
Exp Dermatol; 2023 Jul; 32(7):1063-1071. PubMed ID: 37287089
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
6. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
7. Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa.
Sabat R; Gudjonsson JE; Brembilla NC; van Straalen KR; Wolk K
J Interferon Cytokine Res; 2023 Dec; 43(12):544-556. PubMed ID: 37824200
[TBL] [Abstract][Full Text] [Related]
8. Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies.
Schell SL; Cong Z; Sennett ML; Gettle SL; Longenecker AL; Goldberg SR; Kirby JS; Helm MF; Nelson AM
Br J Dermatol; 2023 Feb; 188(3):407-419. PubMed ID: 36680309
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.
Zouboulis CC
Expert Rev Clin Immunol; 2016 Oct; 12(10):1015-26. PubMed ID: 27531618
[TBL] [Abstract][Full Text] [Related]
10. New and Emerging Targeted Therapies for Hidradenitis Suppurativa.
Markota Čagalj A; Marinović B; Bukvić Mokos Z
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409118
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
12. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
[TBL] [Abstract][Full Text] [Related]
13. S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version.
Zouboulis CC; Bechara FG; Fritz K; Goebeler M; Hetzer FH; Just E; Kirsten N; Kokolakis G; Kurzen H; Nikolakis G; Pinter A; Podda M; Rosinski K; Schneider-Burrus S; Taube KM; Volz T; Winkler T; Kristandt A; Presser D; Zouboulis VA
J Dtsch Dermatol Ges; 2024 Jun; 22(6):868-889. PubMed ID: 38770982
[TBL] [Abstract][Full Text] [Related]
14. Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review.
Sachdeva M; Kim P; Mufti A; Maliyar K; Sibbald C; Alavi A
J Cutan Med Surg; 2022; 26(2):176-180. PubMed ID: 34587768
[TBL] [Abstract][Full Text] [Related]
15. New perspectives on the treatment of hidradenitis suppurativa.
Amat-Samaranch V; Agut-Busquet E; Vilarrasa E; Puig L
Ther Adv Chronic Dis; 2021; 12():20406223211055920. PubMed ID: 34840709
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
[TBL] [Abstract][Full Text] [Related]
17. Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa.
Emelianov VU; Bechara FG; Gläser R; Langan EA; Taungjaruwinai WM; Schröder JM; Meyer KC; Paus R
Br J Dermatol; 2012 May; 166(5):1023-34. PubMed ID: 22136668
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
[No Abstract] [Full Text] [Related]
19. Primary alterations during the development of hidradenitis suppurativa.
Dajnoki Z; Somogyi O; Medgyesi B; Jenei A; Szabó L; Gáspár K; Hendrik Z; Gergely P; Imre D; Póliska S; Törőcsik D; Zouboulis CC; Prens EP; Kapitány A; Szegedi A
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):462-471. PubMed ID: 34724272
[TBL] [Abstract][Full Text] [Related]
20. Matrix remodelling and MMP expression/activation are associated with hidradenitis suppurativa skin inflammation.
Sanchez J; Le Jan S; Muller C; François C; Renard Y; Durlach A; Bernard P; Reguiai Z; Antonicelli F
Exp Dermatol; 2019 May; 28(5):593-600. PubMed ID: 30903721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
